Viking Therapeutics, Inc. Cash and Cash Equivalents
Viking Therapeutics, Inc. (VKTX) had Cash and Cash Equivalents of $125.75 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-07-29
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $125.75M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $118.12M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $165.81M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $100.38M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $125.75M 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $118.12M 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $165.81M 10-Q · filed 2026-07-29 | |
| 2025-09-30 | $100.38M 10-Q · filed 2025-10-23 | |
| 2025-06-30 | $33.88M 10-Q · filed 2025-07-23 | |
| 2025-03-31 | $37.94M 10-Q · filed 2025-04-24 | |
| 2024-12-31 | $26.68M 10-K · filed 2026-02-11 | |
| 2024-09-30 | $50.35M 10-Q · filed 2024-10-23 | |
| 2024-06-30 | $43.91M 10-Q · filed 2024-07-24 | |
| 2024-03-31 | $195.58M 10-Q · filed 2024-04-25 | |
| 2023-12-31 | $55.52M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $37.19M 10-Q · filed 2023-10-25 | |
| 2023-06-30 | $69.52M 10-Q · filed 2023-07-26 | |
| 2023-03-31 | $18.36M 10-Q · filed 2023-04-26 | |
| 2022-12-31 | $36.63M 10-K · filed 2024-02-07 | |
| 2022-09-30 | $29.41M 10-Q · filed 2022-10-26 | |
| 2022-06-30 | $16.23M 10-Q · filed 2022-07-27 | |
| 2022-03-31 | $12.45M 10-Q · filed 2022-04-27 | |
| 2021-12-31 | $26.37M 10-K · filed 2023-02-10 | |
| 2021-09-30 | $11.26M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $8.83M 10-Q · filed 2021-07-28 | |
| 2021-03-31 | $16.80M 10-Q · filed 2021-04-28 | |
| 2020-12-31 | $29.12M 10-K · filed 2022-02-09 | |
| 2020-09-30 | $3.87M 10-Q · filed 2020-10-28 | |
| 2020-06-30 | $18.79M 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $15.26M 10-Q · filed 2020-04-30 | |
| 2019-12-31 | $8.38M 10-K · filed 2021-02-17 | |
| 2019-09-30 | $30.95M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $19.12M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $14.34M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $24.78M 10-K · filed 2020-02-26 | |
| 2018-09-30 | $169.51M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $34.61M 10-Q · filed 2019-08-01 | |
| 2018-03-31 | $36.36M 10-Q · filed 2019-05-02 | |
| 2017-12-31 | $8.99M 10-Q · filed 2019-08-01 | $8.99M 10-K · filed 2018-03-07 |
| 2017-09-30 | $2.57M 10-Q · filed 2018-11-07 | $2.57M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $3.39M 10-Q · filed 2018-08-09 | $3.39M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $4.36M 10-Q · filed 2018-05-09 | $4.36M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $3.08M 10-K · filed 2019-03-13 | $3.08M 10-K · filed 2017-03-21 |
| 2016-09-30 | $3.05M 10-Q · filed 2017-11-08 | |
| 2016-06-30 | $5.16M 10-Q · filed 2017-08-09 | |
| 2016-03-31 | $3.96M 10-Q · filed 2017-05-10 | |
| 2015-12-31 | $768.55K 10-K · filed 2018-03-07 | |
| 2015-09-30 | $2.14M 10-Q · filed 2016-11-10 | |
| 2015-06-30 | $9.50M 10-Q · filed 2016-08-11 | |
| 2015-03-31 | $327.01K 10-Q · filed 2016-05-10 | |
| 2014-12-31 | $755.86K 10-K · filed 2017-03-21 | |
| 2014-09-30 | $794.41K 10-Q · filed 2015-11-05 | |
| 2014-06-30 | $891.48K 10-Q · filed 2015-08-14 | |
| 2014-03-31 | $78.85K 10-Q · filed 2015-06-12 | |
| 2013-12-31 | $179.62K 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |